ESC 2022 | PERSPECTIVE: Efficacy and Safety of Sacubitril/Valsartan Compared with Valsartan in Cognitive Function of Patients with Cardiac Failure and Preserved Function

About 30 to 80% of patients with heart failure (HF) have some sort of cognitive impairment, with a higher risk of dementia than the general population. 

ESC 2022 |

A component of sacubitril/valsartan inhibits neprilysin—an enzyme involved in amyloid-β peptide degradation (Alzheimer’s disease)—, and that could worsen cognitive impairment.

The PERSPECTIVE study is the first randomized trial to assess the long-term effects of sacubitril/valsartan compared with valsartan on the cognitive function of patients with HF and an ejection fraction >40%.

In this study, 592 patients from 137 sites in 20 countries were randomized 1:1. Mean patient age was 72.4 years old, and 46.8% of subjects were female. The primary endpoint (PEP) was cognitive function change at three years, as assessed through the CogState score (GCCS).

There were no significant differences in the PEP when compared with patients treated with valsartan. The analysis was made using the least square mean, with a difference of 0.080 (95% confidence interval: 0.1230-0.0870; p = 0.74). 

Read also: ESC 2022 | SECURE Trial.

In turn, an evaluation of the β-amyloid peptide deposition in the brain was conducted using PET, showing less deposition in patients treated with sacubitrile/valsartan. 

Dr McMurray posited that this study evidences the safety of sacubitrile/valsartan treatment in terms of cognitive function in HF patients.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Font: McMurray J. Neprilysin inhibition does not affectcognitive function in patientswith heart failure (PERSPECTIVE Trial). Presentado en Congreso Europeo de Cardiología ESC 2022. Agosto 26, 2022. Barcelona, España.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

One-Year Mortality Trends Following TAVR: STS/ACC TVT Registry Outcomes

Transcatheter aortic valve replacement (TAVR) has quickly consolidated as a safe and effective treatment option for patients with severe symptomatic aortic stenosis. At present,...

Hyper-Adducted Right Radial Access vs. Left Radial Access: Aiming for Lower Daily Radiation Exposure

Interventional cardiologists face one of the most extreme occupational hazards: ionizing radiation. The right radial access (RRA) has been established as the preferred alternative...

Is Transcarotid Access a Safe Option in TAVI?

Transcatheter aortic valve implantation (TAVI) should preferably be conducted via transfemoral access, according to European guideline (in patients ≥75 years) and American guideline (in patients...